Search Results - "Giagounidis, Aristotles"

Phase I/II Trial of the MEK1/2 Inhibitor Trametinib (GSK1120212) in Relapsed/Refractory Myeloid Malignancies: Evidence of Activity in Patients with RAS Mutation-Positive Disease by Borthakur, Gautam, Popplewell, Leslie, Boyiadzis, Michael, Foran, James M., Platzbecker, Uwe, Vey, Norbert, Roland, Walter B., Olin, Rebecca L., Raza, Azra, Giagounidis, Aristotles, Ottmann, Oliver G., Al-Kali, Aref, Jabbour, Elias J., Kadia, Tapan M., Garcia-Manero, Guillermo, Bauman, John W., Wu, Yuehui, Liu, Yuan, Schramek, Dan, Zhu, John Z., Wissel, Paul, Kantarjian, Hagop M.

“…Abstract 677 Activating mutations of NRAS and KRAS (‘RAS') are found in 10–30% of myeloid malignancies. Evidence of constitutive activation of the…”
Get full text

Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004) by Fenaux, Pierre, Giagounidis, Aristotles, Beyne-Rauzy, Odile, Mufti, Ghulam, Mittelman, Moshe, Muus, Petra, te Boekhorst, Peter, Sanz, Guillermo, Cazzola, Mario, Backstrom, Jay, Fu, Tommy, Hellström-Lindberg, Eva

“…Abstract 4027▪ Transfusion dependence is a significant negative predictor of overall survival (OS) and risk of AML-progression in MDS (Malcovati L, et al. JCO…”
Get full text